10-QPeriod: Q3 FY2017

Medtronic plc Quarterly Report for Q3 Ended Jan 27, 2017

Filed March 3, 2017For Securities:MDT

Summary

Medtronic plc (MDT) reported its third-quarter fiscal year 2017 results, with net sales increasing by 5% to $7.3 billion compared to the prior year's third quarter. This growth was driven by solid performance across its key segments, particularly Cardiac and Vascular Group and Minimally Invasive Therapies Group, with contributions from new product launches and acquisitions. While overall net sales showed positive momentum, net income attributable to Medtronic declined by 25% to $821 million, primarily due to significant charges related to litigation and special contributions. The company also reported a decrease in diluted earnings per share to $0.59 from $0.77 in the prior year's comparable quarter. Despite the decline in net income, Medtronic demonstrated strong operational cash flow, generating $5.1 billion for the nine months ended January 27, 2017, and maintained a healthy free cash flow of $4.2 billion for the same period. The company continues to actively manage its capital structure, including share repurchases and debt management, while investing in research and development to drive future innovation. Investors should note the impact of certain litigation charges and special contributions on the quarter's profitability, which affected the GAAP net income, while the underlying business operations showed resilience.

Financial Highlights

52 data points
Beta

Revenue

$7.28B

68.9% Gross Margin

Net Income

$821.00M

11.3% Net Margin

EPS (Diluted)

$0.59

Total Assets

$97.58B

Cash & Equivalents

$2.77B

Free Cash Flow

$1.76B

Financial Statements
Beta
Revenue$7.28B
Cost of Revenue$2.27B
Gross Profit$5.01B
SG&A Expenses$2.39B
Operating Income$1.15B
Interest Expense$268.00M
Net Income$821.00M
EPS (Basic)$0.60
EPS (Diluted)$0.59
Shares Outstanding (Basic)1.37B
Shares Outstanding (Diluted)1.38B

Key Highlights

  • 1Net sales for the third quarter of fiscal year 2017 increased by 5% year-over-year to $7.3 billion, driven by broad-based growth across segments and contributions from recent acquisitions.
  • 2Net income attributable to Medtronic decreased by 25% to $821 million in the third quarter of fiscal year 2017, impacted by significant special charges and litigation expenses.
  • 3Diluted earnings per share decreased to $0.59 for the third quarter of fiscal year 2017, down from $0.77 in the prior year's comparable quarter.
  • 4The company generated $5.1 billion in cash flow from operating activities for the nine months ended January 27, 2017, and $4.2 billion in free cash flow for the same period.
  • 5Medtronic continued to invest in growth through acquisitions, notably HeartWare International, Inc. and Smith & Nephew's gynecology business, which contributed to net sales.
  • 6Restructuring charges of $21 million and $162 million were recorded for the three and nine months ended January 27, 2017, respectively, largely related to the integration of Covidien.
  • 7The company maintained a strong liquidity position with $2.8 billion in cash and cash equivalents at the end of the quarter and an undrawn $3.5 billion revolving credit facility.

Frequently Asked Questions

Medtronic's net sales grew by 5% to $7.3 billion, primarily driven by strong performance in the Cardiac and Vascular Group, fueled by AF Solutions and Diagnostics, and the Aortic & Peripheral Vascular business. The Minimally Invasive Therapies Group also contributed with solid growth in Surgical Solutions and Patient Monitoring & Recovery. Recent acquisitions, such as HeartWare International and Smith & Nephew's gynecology business, also positively impacted net sales.

The decrease in net income attributable to Medtronic by 25% to $821 million and diluted EPS to $0.59 was largely due to significant charges recorded during the quarter. These included a $100 million special charge for a charitable contribution to the Medtronic Foundation and $218 million in certain litigation charges, which impacted profitability compared to the prior year's period.

Medtronic continues to manage its capital and liquidity effectively. For the nine months ended January 27, 2017, operating cash flow was $5.1 billion and free cash flow was $4.2 billion. The company also repurchased approximately $3.4 billion of its ordinary shares and paid $1.8 billion in dividends to shareholders during the nine-month period. Medtronic maintains a strong liquidity position with $2.8 billion in cash and cash equivalents and an undrawn $3.5 billion revolving credit facility.

Medtronic anticipates continued growth driven by new product launches and market acceptance across its segments. Key areas of focus include the further integration of acquired businesses, expansion of minimally invasive therapies, advancements in diabetes management technology (like the MiniMed 670G system), and innovations in cardiac and vascular devices. However, the company also anticipates potential headwinds from procedural volume changes, competitive pricing pressures, and reimbursement challenges in certain markets.